MEDIVIR, INTERIM REPORT, 1 January – 30 June 2005

• A CD (candidate drug) was designated on the Cathepsin K project (osteoporosis) in May. • BI (Boehringer Ingelheim) concluded its research collaboration with Medivir on the HIV compound MIV-310 (polymerase inhibitor) in March. Medivir has decided to prioritize its protease projects, and accordingly, the MIV-310 project will be dormant until further notice. • Consolidated net sales were SEK 27.2 (12.5) m. • The loss after tax was SEK -73.4 (-92.9) m; earnings per share were SEK -5.69 (-8.64). FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292. FORTHCOMING FINANCIAL INFORMATION The Nine-month Interim Report will be published on 26 October 2005 The Financial Statement will be published on 16 February 2006 The Three-month Interim Report will be published on 26 April 2006 The Annual General Meeting will be on 26 April 2006, from 3 p.m. Medivir’s financial reports are available from its Website, www.medivir.com from these dates.